Knopp Biosciences Partners with MMS Holdings Inc. to Manage Pharmacovigilance Services

Canton, MI (August 1, 2013) – MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole. The MMS Holdings team offers an efficient, adaptable model that enables increased productivity, enhances internal and external reporting, and allows sponsors more time to focus on strategy rather than day-to-day activities. MMS Holdings has strong processes and systems in place as well as experienced, qualified staff, producing a comprehensive pharmacovigilance and risk management solution.

Read more


Comments are closed.